+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Pharmaceutical Contract Development & Manufacturing Market by Service Type (Contract Development Services, Contract Manufacturing Services), Development Stage (Clinical, Commercial, Preclinical), End Use, Customer Type - Global Forecast 2025-2030- Product Image
Pharmaceutical Contract Development & Manufacturing Market by Service Type (Contract Development Services, Contract Manufacturing Services), Development Stage (Clinical, Commercial, Preclinical), End Use, Customer Type - Global Forecast 2025-2030- Product Image
Sale

Pharmaceutical Contract Development & Manufacturing Market by Service Type (Contract Development Services, Contract Manufacturing Services), Development Stage (Clinical, Commercial, Preclinical), End Use, Customer Type - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 191 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 4829832
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Pharmaceutical Contract Development & Manufacturing Market grew from USD 136.27 billion in 2024 to USD 148.06 billion in 2025. It is expected to continue growing at a CAGR of 8.49%, reaching USD 222.23 billion by 2030.

Setting the Stage for Strategic Insight into Pharmaceutical Contract Development and Manufacturing Evolution without Compromising Depth or Clarity

The global pharmaceutical contract development and manufacturing sector continues to redefine the contours of innovation and efficiency in drug discovery and production. Against the backdrop of escalating demand for specialized services, stakeholders from emerging biotechnology firms to established innovator companies are seeking agile partners capable of accelerating timelines and mitigating risks. This environment has spurred the rise of service providers that seamlessly integrate analytical development, process optimization, and commercial-scale manufacturing under a single umbrella.

As the landscape becomes increasingly fragmented and competitive, there is a pressing need for decision-makers to understand not only the technological capabilities and capacity footprints of their potential collaborators but also the strategic trends driving consolidation and differentiation. In response, this executive summary synthesizes the critical drivers, challenges, and opportunities shaping contract development services-from clinical trial material manufacturing and drug formulation to advanced analytical testing-and contract manufacturing services, encompassing API production, finished dosage form operations, and specialized packaging solutions.

Unveiling the Dynamic Forces Reshaping Pharmaceutical Contract Development and Manufacturing through Technological Innovation and Strategic Realignment

The pharmaceutical contract development and manufacturing ecosystem is undergoing profound transformation, powered by advances in continuous manufacturing, single-use technologies, and modular facility designs. These innovations are not only enhancing the speed and flexibility of production but also reducing contamination risk and capital expenditures. Moreover, the proliferation of gene and cell therapies has elevated demand for highly specialized process development expertise, driving a surge in targeted investments and collaborative research partnerships.

Simultaneously, digitalization has emerged as a cornerstone of operational excellence, with real-time process monitoring, predictive maintenance, and data analytics enabling more robust quality assurance and faster time-to-market. In this context, leading service providers are forming strategic alliances with technology firms and academic centers to co-develop next-generation manufacturing platforms. Together, these shifts are redefining partner selection criteria, with sponsors prioritizing organizations that demonstrate both deep technical acumen and an agile, digitally enabled infrastructure.

Analyzing the Cumulative Ramifications of United States Tariffs in 2025 on the Pharmaceutical Contract Development and Manufacturing Landscape

The imposition of new tariff measures in 2025 by United States authorities on select chemical intermediates and pharmaceutical components has compelled organizations to reassess global supply chain configurations. As costs for imported active pharmaceutical ingredients and specialized excipients escalate, contract development and manufacturing entities are recalibrating their sourcing strategies to maintain margin integrity. Many are deepening local procurement or diversifying supplier portfolios to alleviate tariff-related expense inflation.

Furthermore, the ripple effects of these tariffs are manifesting in strategic relocations of high-value process development and manufacturing activities closer to end markets. This realignment not only mitigates trade barriers but also accelerates lead times and strengthens contingency planning against future policy shifts. In response, cross-border project planning has evolved to incorporate dynamic cost modeling and scenario analysis, enabling sponsors and service partners to safeguard project viability amidst an increasingly volatile trade environment.

Delivering Actionable Market Intelligence through Segmentation Analysis Spotlighting Service Types Development Stages End Uses and Customer Types

Segmenting the market by service type reveals two dominant categories: contract development services and contract manufacturing services. Within contract development, analytical development, clinical trial material manufacturing, drug formulation development, and process development each play a pivotal role in de-risking early-stage programs and ensuring regulatory compliance. On the manufacturing side, specialized capabilities in active pharmaceutical ingredient manufacturing, finished dosage form production, and packaging services enable seamless transition from pilot workflows to commercial supply chain operations.

When assessing the evolution stage of drug candidates, preclinical, clinical, and commercial phases dictate divergent service requirements. Preclinical programs necessitate small-scale toxicology batches and formulation stability assessments, whereas clinical trials, from Phase I through Phase III, demand robust quality systems and adherence to Good Manufacturing Practices at escalating scales. Commercial programs, by contrast, require sustained capacity, cost optimization, and continuous process verification.

The range of therapeutic areas served further nuances market dynamics. High-value segments such as oncology and infectious diseases stimulate demand for complex manufacturing platforms, while therapies targeting cardiovascular and central nervous system disorders drive steady demand for conventional small-molecule production and formulation expertise. Equally important, the typology of clients-spanning biosimilar manufacturers, biotechnology companies, generic pharmaceutical firms, and innovator pharmaceutical organizations-dictates distinct service preferences, risk tolerance profiles, and partnership models.

Unraveling Regional Market Dynamics across the Americas Europe Middle East Africa and Asia Pacific with Strategic Focus on Growth Opportunities

Regional market dynamics in the Americas are characterized by robust capacity expansions and a concentration of integrated service providers supporting both small-molecule and biologics pipelines. Key hubs in North America leverage advanced digital infrastructure and streamlined regulatory pathways, enabling swift scale-up of both clinical-stage and commercial operations. Meanwhile, Latin America is emerging as a promising near-shore alternative for cost-effective manufacturing and secondary packaging.

In Europe, the Middle East, and Africa, regulatory harmonization efforts across the European Union and collaborations within pan-regional pharmaceutical clusters are driving standardized quality benchmarks and fostering cross-border project coordination. This region’s deep reservoir of technical talent and strong academic-industry linkages also support rapid adoption of continuous processing technologies. Conversely, the African segment is gaining traction as stakeholders invest in foundational infrastructure to serve local markets and address unmet medical needs.

Across the Asia-Pacific theater, the landscape is dominated by large-scale API manufacturers, contract development specialists, and clinical trial material producers. China, India, and Southeast Asian economies offer compelling cost advantages, while Japan and South Korea continue to lead in advanced biologics development. These markets are rapidly integrating digital quality control systems and investing in environmentally conscious production methods to align with global sustainability mandates.

Mapping Competitive Landscapes and Identifying Key Industry Players Driving Innovation Partnerships and Capacity Expansion in Pharmaceutical Manufacturing

The competitive landscape is anchored by global service providers that have scaled through strategic acquisitions, capacity expansions, and extensive technology portfolios. These industry leaders continuously invest in next-generation manufacturing platforms, such as continuous flow chemistry and single-use bioreactors, to meet evolving client requirements. At the same time, a cadre of specialized, regionally focused players is carving out niches in areas like high-potency API production, complex injectable formulation, and advanced cell therapy manufacturing.

Partnerships between incumbent contract manufacturers and biotech innovators are becoming increasingly prevalent, facilitating co-development of novel delivery mechanisms and personalized medicine solutions. In parallel, alliances with academic centers and technology vendors are accelerating access to emerging modalities, such as mRNA and gene editing. Across all tiers, capacity optimization through multi-purpose facilities and flexible manufacturing suites remains a differentiator in securing long-term client engagements and mitigating project risks.

Crafting Strategic Recommendations to Propel Growth Enhance Operational Efficiency and Foster Innovation in Pharmaceutical Contract Development and Manufacturing

To thrive in this dynamic environment, stakeholders should prioritize the integration of advanced digital platforms for real-time process analytical technology and predictive maintenance. Strengthening end-to-end transparency across development and manufacturing workflows will bolster regulatory readiness and minimize quality deviations. Moreover, forging strategic alliances with technology purveyors and academic institutions can accelerate access to transformative modalities while sharing development risks.

Diversifying service portfolios to encompass both small-molecule and biologics capabilities, as well as early-stage process development and late-stage commercial manufacturing, will position providers as indispensable partners. Furthermore, embedding sustainability practices-ranging from solvent recycling to energy-efficient production processes-will address both regulatory pressures and client ESG mandates. Ultimately, a balanced approach that couples operational excellence with strategic innovation will be the hallmark of leaders in the contract development and manufacturing arena.

Outlining the Robust Research Methodology Underpinning the Analysis Including Data Collection Validation and Expert Perspectives Ensuring Credibility

This analysis is founded on a rigorous research framework incorporating primary and secondary data sources. Extensive interviews with executive-level decision-makers at pharmaceutical companies and contract service providers provided nuanced perspectives on market opportunities, operational challenges, and technological priorities. Secondary research drew upon industry publications, regulatory filings, and patent databases to validate emerging trends and corroborate company activities.

Quantitative data on capacity expansions, investment volumes, and technology adoption rates were triangulated across multiple reliable sources, ensuring robustness and minimizing bias. An advisory panel of subject-matter experts reviewed preliminary findings, lending credibility and refining strategic recommendations. This methodical approach ensures confidence in the insights presented and their applicability to strategic decision-making in contract development and manufacturing.

Drawing Conclusive Insights and Summarizing the Strategic Imperatives for Stakeholders in the Evolving Pharmaceutical Contract Development and Manufacturing

The pharmaceutical contract development and manufacturing sector stands at a pivotal juncture, shaped by rapid technological advancements, evolving regulatory landscapes, and shifting global trade policies. Stakeholders must navigate complex segmentation dynamics, from service offerings and development stages to therapeutic focus areas and client typologies. Moreover, regional nuances and competitive differentiators demand tailored strategies to capture growth and mitigate risks.

By embracing digitalization, fostering strategic collaborations, and reinforcing supply chain resilience, organizations can accelerate time-to-market and sustain operational excellence. Investing in sustainability and regulatory harmonization will not only meet stakeholder expectations but also unlock new commercial opportunities. In sum, proactive adaptation to these imperatives will be critical for both service providers and sponsors seeking to maintain leadership in the evolving pharmaceutical contract development and manufacturing landscape.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Service Type
    • Contract Development Services
      • Analytical Development
      • Clinical Trial Material Manufacturing
      • Drug Formulation Development
      • Process Development
    • Contract Manufacturing Services
      • Active Pharmaceutical Ingredient (API) Manufacturing
      • Finished Dosage Form (FDF) Manufacturing
      • Packaging Services
  • Development Stage
    • Clinical
      • Phase I
      • Phase II
      • Phase III
    • Commercial
    • Preclinical
  • End Use
    • Cardiovascular
    • Central Nervous System
    • Infectious Diseases
    • Oncology
  • Customer Type
    • Biosimilar Manufacturer
    • Biotechnology Company
    • Generic Pharma
    • Innovator Pharma
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report delves into recent significant developments and analyzes trends in each of the following companies:
  • Thermo Fisher Scientific Inc.
  • Lonza Group AG
  • Catalent Inc.
  • Recipharm AB
  • Samsung Biologics Co., Ltd.
  • WuXi AppTec Co., Ltd.
  • Boehringer Ingelheim International GmbH
  • AGC Biologics Inc.
  • Siegfried Holding AG
  • Fareva Holding SAS

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Advancements in continuous manufacturing platforms for small molecule API production
5.2. Integration of artificial intelligence for process optimization in biologics development
5.3. Rising demand for personalized medicine driving expansion of customizable fill and finish services
5.4. Regulatory harmonization challenges influencing quality management systems across global CDMO networks
5.5. Strategic partnerships between CDMOs and emerging biotech firms to accelerate novel modality pipelines
5.6. Implementation of digital twin technology to enhance real-time monitoring in drug manufacturing plants
5.7. Expansion of cold chain logistics infrastructure to support growing mRNA and cell therapy supply chains
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Pharmaceutical Contract Development & Manufacturing Market, by Service Type
8.1. Introduction
8.2. Contract Development Services
8.2.1. Analytical Development
8.2.2. Clinical Trial Material Manufacturing
8.2.3. Drug Formulation Development
8.2.4. Process Development
8.3. Contract Manufacturing Services
8.3.1. Active Pharmaceutical Ingredient (API) Manufacturing
8.3.2. Finished Dosage Form (FDF) Manufacturing
8.3.3. Packaging Services
9. Pharmaceutical Contract Development & Manufacturing Market, by Development Stage
9.1. Introduction
9.2. Clinical
9.2.1. Phase I
9.2.2. Phase II
9.2.3. Phase III
9.3. Commercial
9.4. Preclinical
10. Pharmaceutical Contract Development & Manufacturing Market, by End Use
10.1. Introduction
10.2. Cardiovascular
10.3. Central Nervous System
10.4. Infectious Diseases
10.5. Oncology
11. Pharmaceutical Contract Development & Manufacturing Market, by Customer Type
11.1. Introduction
11.2. Biosimilar Manufacturer
11.3. Biotechnology Company
11.4. Generic Pharma
11.5. Innovator Pharma
12. Americas Pharmaceutical Contract Development & Manufacturing Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Pharmaceutical Contract Development & Manufacturing Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Pharmaceutical Contract Development & Manufacturing Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. Thermo Fisher Scientific Inc.
15.3.2. Lonza Group AG
15.3.3. Catalent Inc.
15.3.4. Recipharm AB
15.3.5. Samsung Biologics Co., Ltd.
15.3.6. WuXi AppTec Co., Ltd.
15.3.7. Boehringer Ingelheim International GmbH
15.3.8. AGC Biologics Inc.
15.3.9. Siegfried Holding AG
15.3.10. Fareva Holding SAS
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CUSTOMER TYPE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CUSTOMER TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 14. AMERICAS PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 16. UNITED STATES PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 22. PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 23. PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET: RESEARCHAI
FIGURE 24. PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET: RESEARCHSTATISTICS
FIGURE 25. PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET: RESEARCHCONTACTS
FIGURE 26. PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY ANALYTICAL DEVELOPMENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY ANALYTICAL DEVELOPMENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CLINICAL TRIAL MATERIAL MANUFACTURING, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CLINICAL TRIAL MATERIAL MANUFACTURING, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DRUG FORMULATION DEVELOPMENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DRUG FORMULATION DEVELOPMENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY ACTIVE PHARMACEUTICAL INGREDIENT (API) MANUFACTURING, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY ACTIVE PHARMACEUTICAL INGREDIENT (API) MANUFACTURING, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY FINISHED DOSAGE FORM (FDF) MANUFACTURING, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY FINISHED DOSAGE FORM (FDF) MANUFACTURING, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PACKAGING SERVICES, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PACKAGING SERVICES, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CLINICAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CLINICAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHASE I, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHASE I, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHASE II, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHASE II, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHASE III, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHASE III, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CLINICAL, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CLINICAL, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY COMMERCIAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY COMMERCIAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PRECLINICAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PRECLINICAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CUSTOMER TYPE, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CUSTOMER TYPE, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOSIMILAR MANUFACTURER, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOSIMILAR MANUFACTURER, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOTECHNOLOGY COMPANY, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOTECHNOLOGY COMPANY, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY GENERIC PHARMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY GENERIC PHARMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY INNOVATOR PHARMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY INNOVATOR PHARMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. AMERICAS PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
TABLE 70. AMERICAS PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
TABLE 71. AMERICAS PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2018-2024 (USD MILLION)
TABLE 72. AMERICAS PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2025-2030 (USD MILLION)
TABLE 73. AMERICAS PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2018-2024 (USD MILLION)
TABLE 74. AMERICAS PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2025-2030 (USD MILLION)
TABLE 75. AMERICAS PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
TABLE 76. AMERICAS PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2030 (USD MILLION)
TABLE 77. AMERICAS PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CLINICAL, 2018-2024 (USD MILLION)
TABLE 78. AMERICAS PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CLINICAL, 2025-2030 (USD MILLION)
TABLE 79. AMERICAS PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
TABLE 80. AMERICAS PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
TABLE 81. AMERICAS PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CUSTOMER TYPE, 2018-2024 (USD MILLION)
TABLE 82. AMERICAS PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CUSTOMER TYPE, 2025-2030 (USD MILLION)
TABLE 83. AMERICAS PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 84. AMERICAS PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 85. UNITED STATES PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
TABLE 86. UNITED STATES PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
TABLE 87. UNITED STATES PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2018-2024 (USD MILLION)
TABLE 88. UNITED STATES PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2025-2030 (USD MILLION)
TABLE 89. UNITED STATES PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2018-2024 (USD MILLION)
TABLE 90. UNITED STATES PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2025-2030 (USD MILLION)
TABLE 91. UNITED STATES PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
TABLE 92. UNITED STATES PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2030 (USD MILLION)
TABLE 93. UNITED STATES PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CLINICAL, 2018-2024 (USD MILLION)
TABLE 94. UNITED STATES PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CLINICAL, 2025-2030 (USD MILLION)
TABLE 95. UNITED STATES PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
TABLE 96. UNITED STATES PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
TABLE 97. UNITED STATES PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CUSTOMER TYPE, 2018-2024 (USD MILLION)
TABLE 98. UNITED STATES PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CUSTOMER TYPE, 2025-2030 (USD MILLION)
TABLE 99. UNITED STATES PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 100. UNITED STATES PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 101. CANADA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
TABLE 102. CANADA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
TABLE 103. CANADA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2018-2024 (USD MILLION)
TABLE 104. CANADA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2025-2030 (USD MILLION)
TABLE 105. CANADA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2018-2024 (USD MILLION)
TABLE 106. CANADA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2025-2030 (USD MILLION)
TABLE 107. CANADA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
TABLE 108. CANADA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2030 (USD MILLION)
TABLE 109. CANADA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CLINICAL, 2018-2024 (USD MILLION)
TABLE 110. CANADA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CLINICAL, 2025-2030 (USD MILLION)
TABLE 111. CANADA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
TABLE 112. CANADA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
TABLE 113. CANADA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CUSTOMER TYPE, 2018-2024 (USD MILLION)
TABLE 114. CANADA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CUSTOMER TYPE, 2025-2030 (USD MILLION)
TABLE 115. MEXICO PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
TABLE 116. MEXICO PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
TABLE 117. MEXICO PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2018-2024 (USD MILLION)
TABLE 118. MEXICO PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2025-2030 (USD MILLION)
TABLE 119. MEXICO PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2018-2024 (USD MILLION)
TABLE 120. MEXICO PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2025-2030 (USD MILLION)
TABLE 121. MEXICO PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
TABLE 122. MEXICO PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2030 (USD MILLION)
TABLE 123. MEXICO PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CLINICAL, 2018-2024 (USD MILLION)
TABLE 124. MEXICO PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CLINICAL, 2025-2030 (USD MILLION)
TABLE 125. MEXICO PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
TABLE 126. MEXICO PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
TABLE 127. MEXICO PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CUSTOMER TYPE, 2018-2024 (USD MILLION)
TABLE 128. MEXICO PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CUSTOMER TYPE, 2025-2030 (USD MILLION)
TABLE 129. BRAZIL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
TABLE 130. BRAZIL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
TABLE 131. BRAZIL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2018-2024 (USD MILLION)
TABLE 132. BRAZIL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2025-2030 (USD MILLION)
TABLE 133. BRAZIL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2018-2024 (USD MILLION)
TABLE 134. BRAZIL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2025-2030 (USD MILLION)
TABLE 135. BRAZIL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
TABLE 136. BRAZIL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2030 (USD MILLION)
TABLE 137. BRAZIL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CLINICAL, 2018-2024 (USD MILLION)
TABLE 138. BRAZIL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CLINICAL, 2025-2030 (USD MILLION)
TABLE 139. BRAZIL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
TABLE 140. BRAZIL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
TABLE 141. BRAZIL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CUSTOMER TYPE, 2018-2024 (USD MILLION)
TABLE 142. BRAZIL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CUSTOMER TYPE, 2025-2030 (USD MILLION)
TABLE 143. ARGENTINA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
TABLE 144. ARGENTINA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
TABLE 145. ARGENTINA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2018-2024 (USD MILLION)
TABLE 146. ARGENTINA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2025-2030 (USD MILLION)
TABLE 147. ARGENTINA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2018-2024 (USD MILLION)
TABLE 148. ARGENTINA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2025-2030 (USD MILLION)
TABLE 149. ARGENTINA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
TABLE 150. ARGENTINA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2030 (USD MILLION)
TABLE 151. ARGENTINA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CLINICAL, 2018-2024 (USD MILLION)
TABLE 152. ARGENTINA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CLINICAL, 2025-2030 (USD MILLION)
TABLE 153. ARGENTINA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
TABLE 154. ARGENTINA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
TABLE 155. ARGENTINA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CUSTOMER TYPE, 2018-2024 (USD MILLION)
TABLE 156. ARGENTINA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CUSTOMER TYPE, 2025-2030 (USD MILLION)
TABLE 157. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
TABLE 158. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
TABLE 159. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2018-2024 (USD MILLION)
TABLE 160. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2025-2030 (USD MILLION)
TABLE 161. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2018-2024 (USD MILLION)
TABLE 162. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2025-2030 (USD MILLION)
TABLE 163. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
TABLE 164. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2030 (USD MILLION)
TABLE 165. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CLINICAL, 2018-2024 (USD MILLION)
TABLE 166. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CLINICAL, 2025-2030 (USD MILLION)
TABLE 167. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
TABLE 168. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
TABLE 169. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CUSTOMER TYPE, 2018-2024 (USD MILLION)
TABLE 170. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CUSTOMER TYPE, 2025-2030 (USD MILLION)
TABLE 171. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 172. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 173. UNITED KINGDOM PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
TABLE 174. UNITED KINGDOM PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
TABLE 175. UNITED KINGDOM PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2018-2024 (USD MILLION)
TABLE 176. UNITED KINGDOM PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2025-2030 (USD MILLION)
TABLE 177. UNITED KINGDOM PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2018-2024 (USD MILLION)
TABLE 178. UNITED KINGDOM PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2025-2030 (USD MILLION)
TABLE 179. UNITED KINGDOM PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
TABLE 180. UNITED KINGDOM PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2030 (USD MILLION)
TABLE 181. UNITED KINGDOM PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CLINICAL, 2018-2024 (USD MILLION)
TABLE 182. UNITED KINGDOM PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CLINICAL, 2025-2030 (USD MILLION)
TABLE 183. UNITED KINGDOM PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
TABLE 184. UNITED KINGDOM PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
TABLE 185. UNITED KINGDOM PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CUSTOMER TYPE, 2018-2024 (USD MILLION)
TABLE 186. UNITED KINGDOM PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CUSTOMER TYPE, 2025-2030 (USD MILLION)
TABLE 187. GERMANY PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
TABLE 188. GERMANY PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
TABLE 189. GERMANY PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2018-2024 (USD MILLION)
TABLE 190. GERMANY PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2025-2030 (USD MILLION)
TABLE 191. GERMANY PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2018-2024 (USD MILLION)
TABLE 192. GERMANY PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2025-2030 (USD MILLION)
TABLE 193. GERMANY PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
TABLE 194. GERMANY PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2030 (USD MILLION)
TABLE 195. GERMANY PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CLINICAL, 2018-2024 (USD MILLION)
TABLE 196. GERMANY PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CLINICAL, 2025-2030 (USD MILLION)
TABLE 197. GERMANY PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
TABLE 198. GERMANY PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
TABLE 199. GERMANY PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CUSTOMER TYPE, 2018-2024 (USD MILLION)
TABLE 200. GERMANY PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CUSTOMER TYPE, 2025-2030 (USD MILLION)
TABLE 201. FRANCE PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
TABLE 202. FRANCE PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
TABLE 203. FRANCE PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2018-2024 (USD MILLION)
TABLE 204. FRANCE PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2025-2030 (USD MILLION)
TABLE 205. FRANCE PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2018-2024 (USD MILLION)
TABLE 206. FRANCE PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2025-2030 (USD MILLION)
TABLE 207. FRANCE PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
TABLE 208. FRANCE PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2030 (USD MILLION)
TABLE 209. FRANCE PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CLINICAL, 2018-2024 (USD MILLION)
TABLE 210. FRANCE PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CLINICAL, 2025-2030 (USD MILLION)
TABLE 211. FRANCE PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
TABLE 212. FRANCE PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
TABLE 213. FRANCE PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CUSTOMER TYPE, 2018-2024 (USD MILLION)
TABLE 214. FRANCE PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CUSTOMER TYPE, 2025-2030 (USD MILLION)
TABLE 215. RUSSIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
TABLE 216. RUSSIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
TABLE 217. RUSSIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2018-2024 (USD MILLION)
TABLE 218. RUSSIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2025-2030 (USD MILLION)
TABLE 219. RUSSIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2018-2024 (USD MILLION)
TABLE 220. RUSSIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2025-2030 (USD MILLION)
TABLE 221. RUSSIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
TABLE 222. RUSSIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2030 (USD MILLION)
TABLE 223. RUSSIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CLINICAL, 2018-2024 (USD MILLION)
TABLE 224. RUSSIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CLINICAL, 2025-2030 (USD MILLION)
TABLE 225. RUSSIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
TABLE 226. RUSSIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
TABLE 227. RUSSIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CUSTOMER TYPE, 2018-2024 (USD MILLION)
TABLE 228. RUSSIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CUSTOMER TYPE, 2025-2030 (USD MILLION)
TABLE 229. ITALY PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
TABLE 230. ITALY PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
TABLE 231. ITALY PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2018-2024 (USD MILLION)
TABLE 232. ITALY PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2025-2030 (USD MILLION)
TABLE 233. ITALY PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2018-2024 (USD MILLION)
TABLE 234. ITALY PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2025-2030 (USD MILLION)
TABLE 235. ITALY PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
TABLE 236. ITALY PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2030 (USD MILLION)
TABLE 237. ITALY PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CLINICAL, 2018-2024 (USD MILLION)
TABLE 238. ITALY PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CLINICAL, 2025-2030 (USD MILLION)
TABLE 239. ITALY PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
TABLE 240. ITALY PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
TABLE 241. ITALY PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CUSTOMER TYPE, 2018-2024 (USD MILLION)
TABLE 242. ITALY PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CUSTOMER TYPE, 2025-2030 (USD MILLION)
TABLE 243. SPAIN PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
TABLE 244. SPAIN PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
TABLE 245. SPAIN PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2018-2024 (USD MILLION)
TABLE 246. SPAIN PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2025-2030 (USD MILLION)
TABLE 247. SPAIN PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2018-2024 (USD

Samples

Loading
LOADING...

Companies Mentioned

  • Thermo Fisher Scientific Inc.
  • Lonza Group AG
  • Catalent Inc.
  • Recipharm AB
  • Samsung Biologics Co., Ltd.
  • WuXi AppTec Co., Ltd.
  • Boehringer Ingelheim International GmbH
  • AGC Biologics Inc.
  • Siegfried Holding AG
  • Fareva Holding SAS

Table Information

Report AttributeDetails
No. of Pages191
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 148.06 Billion
Forecasted Market Value ( USD ) by 2030 $ 222.23 Billion
Compound Annual Growth Rate8.4%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Pharmaceutical Contract Manufacturing Market by Service Type, Molecule Type, Dosage Form, Customer Type, Therapeutic Area, Contract Type, Production Scale, Process Type - Global Forecast 2025-2030 - Product Image

Pharmaceutical Contract Manufacturing Market by Service Type, Molecule Type, Dosage Form, Customer Type, Therapeutic Area, Contract Type, Production Scale, Process Type - Global Forecast 2025-2030

  • Report
  • 197 Pages
  • Global
From
Pharmaceutical Contract Manufacturing & Research Services Market by Service Type (Consulting Services, Manufacturing Services, Research Services), End-User (Academic & Government Research Institutes, Biotechnology Companies, Pharmaceutical Companies) - Global Forecast 2025-2030 - Product Image

Pharmaceutical Contract Manufacturing & Research Services Market by Service Type (Consulting Services, Manufacturing Services, Research Services), End-User (Academic & Government Research Institutes, Biotechnology Companies, Pharmaceutical Companies) - Global Forecast 2025-2030

  • Report
  • 195 Pages
  • Global
From
Pharmaceutical Contract Manufacturing Market Size, Share & Trends Analysis Report by Product (Small Molecule, Biologics), Drug, Service, Scale of Operation, Workflow, Application, End Use, Company, and Region with Growth Forecasts, 2025-2030 - Product Image

Pharmaceutical Contract Manufacturing Market Size, Share & Trends Analysis Report by Product (Small Molecule, Biologics), Drug, Service, Scale of Operation, Workflow, Application, End Use, Company, and Region with Growth Forecasts, 2025-2030

  • Report
  • 150 Pages
  • Global
From
Generic Pharmaceuticals Contract Manufacturing Market Size, Share & Trends Analysis Report By Drug Type (Branded, Unbranded), By Product (API, Drug Product), By Route Of Administration, By Application, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Generic Pharmaceuticals Contract Manufacturing Market Size, Share & Trends Analysis Report By Drug Type (Branded, Unbranded), By Product (API, Drug Product), By Route Of Administration, By Application, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 150 Pages
  • Global
From
Oligonucleotide CDMO Market by Service (Contract Manufacturing (Clinical, Commercial), Development), Type (ASO, SiRNA, (CPG Oligos, gRNA)), Application (Therapeutic, Research, Diagnostic), End User (Pharma, Biotech) - Global Forecast to 2029 - Product Image

Oligonucleotide CDMO Market by Service (Contract Manufacturing (Clinical, Commercial), Development), Type (ASO, SiRNA, (CPG Oligos, gRNA)), Application (Therapeutic, Research, Diagnostic), End User (Pharma, Biotech) - Global Forecast to 2029

  • Report
  • 255 Pages
  • Global
From

About the Pharmaceutical Contract Management Market

The Pharmaceutical Contract Management market is an important part of the drug discovery process. It involves the management of contracts between pharmaceutical companies and research organizations, such as universities and biotechnology companies. These contracts are used to facilitate the development of new drugs and treatments. The contract management process includes the negotiation of terms, the management of payments, and the tracking of progress. It also involves the management of intellectual property rights, such as patents and copyrights. The Pharmaceutical Contract Management market is highly competitive, with many companies offering services to pharmaceutical companies. These companies provide a range of services, including contract negotiation, contract management, and intellectual property management. Some of the leading companies in the market include Accenture, Deloitte, Parexel, and Syneos Health. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.